In summary, while it is possible that ALK-positive NSCLC in itself may constitute a major risk factor for the development of complex renal cysts, treatment with crizotinib appears to be associated with an increased risk for the development and progression of renal cysts in patients with ALK-positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.